THTX Stock Overview
A biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Theratechnologies Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$1.24 |
| 52 Week High | CA$4.20 |
| 52 Week Low | CA$0.88 |
| Beta | 1.81 |
| 1 Month Change | -10.14% |
| 3 Month Change | -24.16% |
| 1 Year Change | -67.37% |
| 3 Year Change | -91.46% |
| 5 Year Change | -93.80% |
| Change since IPO | -93.54% |
Recent News & Updates
Shareholder Returns
| THTX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -5.3% | 0.07% | -0.2% |
| 1Y | -67.4% | 6.9% | 28.2% |
Return vs Industry: THTX underperformed the US Biotechs industry which returned 6.9% over the past year.
Return vs Market: THTX underperformed the US Market which returned 28.2% over the past year.
Price Volatility
| THTX volatility | |
|---|---|
| THTX Average Weekly Movement | 9.6% |
| Biotechs Industry Average Movement | 11.3% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 16.0% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: THTX's share price has been volatile over the past 3 months.
Volatility Over Time: THTX's weekly volatility has decreased from 17% to 10% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 103 | Paul Lévesque | www.theratech.com |
Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen. Its pipeline products include F8 Formulation that is in Phase 2b/3 clinical trials for studying tesamorelin for the treatment of nonalcoholic steatohepatitis; multi -dose pen injector for the administration of tesamorelin; SORT1+ Technology Platform for the development of proprietary peptides for cancer drug development targeting SORT1 receptors; Sudocetaxel Zendusortide, which is in Phase 1 Clinical Trial for various solid tumor types, including HR+ breast, triple negative breast, ovarian, endometrial, melanoma, thyroid, small cell lung, and prostate cancers.
Theratechnologies Inc. Fundamentals Summary
| THTX fundamental statistics | |
|---|---|
| Market cap | US$59.08m |
| Earnings (TTM) | -US$17.99m |
| Revenue (TTM) | US$78.10m |
0.7x
P/S Ratio-3.2x
P/E RatioIs THTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| THTX income statement (TTM) | |
|---|---|
| Revenue | US$78.10m |
| Cost of Revenue | US$20.23m |
| Gross Profit | US$57.88m |
| Other Expenses | US$75.87m |
| Earnings | -US$17.99m |
Last Reported Earnings
Feb 29, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.39 |
| Gross Margin | 74.10% |
| Net Profit Margin | -23.04% |
| Debt/Equity Ratio | -236.8% |
How did THTX perform over the long term?
See historical performance and comparison